The genetic architecture of multiple myeloma

Nature Reviews Cancer

Volumn 12, Issue 5, 2012, Pages 335-348

  Morgan, Gareth J ^a   Walker, Brian A ^a   Davies, Faith E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE; CANCER RESISTANCE; CELLULAR IMMUNITY; CHROMOSOME TRANSLOCATION; COPY NUMBER VARIATION; DISEASE COURSE; EPIGENETICS; GENE DELETION; GENE MUTATION; GENE STRUCTURE; GENETIC VARIABILITY; HUMAN; MOLECULAR EVOLUTION; MULTIPLE MYELOMA; MYELOMA CELL; ONCOGENE; PLASMA CELL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; UNFOLDED PROTEIN RESPONSE;

ANIMALS; CLONAL EVOLUTION; DISEASE PROGRESSION; GENETIC HETEROGENEITY; HUMANS; MULTIPLE MYELOMA; PLASMA CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860219443     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3257     Document Type: Review

References (114)

1. Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412-3420 (2005).
2. Kyle, R. A. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78, 21-33 (2003). (Pubitemid 36033957)
3. Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582-2590 (2007). (Pubitemid 46961003)
4. Akiyama, M. et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 62, 3876-3882 (2002). (Pubitemid 34728875)
5. Chauhan, D. et al. Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene 23, 3597-3602 (2004). (Pubitemid 38658426)
6. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658-1667 (1999). (Pubitemid 29102494)
7. Hideshima, T. et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107, 4053-4062 (2006). (Pubitemid 43726814)
8. Mitsiades, C. S., Mitsiades, N. S., Munshi, N. C., Richardson, P. G. & Anderson, K. C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer 42, 1564-1573 (2006). (Pubitemid 44118771)
9. Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046-1060 (2011).
10. Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
11. Gonzalez, D. et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110, 3112-3121 (2007). (Pubitemid 350106301)
12. Bergsagel, P. L. & Kuehl, W. M. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol. Rev. 194, 96-104 (2003). (Pubitemid 36886431)
13. Hakim, O. et al. DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes. Nature 7 Feb 2012 (doi:10.1038/nature10909).
14. Reimold, A. M. et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 412, 300-307 (2001). (Pubitemid 32691837)
15. Iwakoshi, N. N. et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nature Immunol. 4, 321-329 (2003). (Pubitemid 36432313)
16. Shaffer, A. L. et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21, 81-93 (2004). (Pubitemid 38925269)
17. Davenport, E. L., Morgan, G. J. & Davies, F. E. Untangling the unfolded protein response. Cell Cycle 7, 865-869 (2008). (Pubitemid 351573778)
18. Carrasco, D. R. et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11, 349-360 (2007). (Pubitemid 46518314)
19. Bagratuni, T. et al. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood 116, 250-253 (2010).
20. Oracki, S. A., Walker, J. A., Hibbs, M. L., Corcoran, L. M. & Tarlinton, D. M. Plasma cell development and survival. Immunol. Rev. 237, 140-159 (2010).
21. Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nature Rev. Immunol. 6, 741-750 (2006). (Pubitemid 44453460)
22. Chiecchio, L. et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 94, 1708-1713 (2009).
23. Carrasco, D. R. et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9, 313-325 (2006).
24. Walker, B. A. et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116, e56-e65 (2010).
25. Lopez-Corral, L. et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin. Cancer Res. 17, 1692-1700 (2011).
26. Cremer, F. W. et al. High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH. Cancer Genet. Cytogenet. 161, 116-124 (2005). (Pubitemid 41133477)
27. Walker, B. A. et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms and genes important in the pathogenesis of multiple myeloma. Blood 108, 1733-1743 (2006). (Pubitemid 44316144)
28. Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356-361 (2011).
29. Sahota, S. S., Leo, R., Hamblin, T. J. & Stevenson, F. K. Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Blood 87, 746-755 (1996).
30. Ross, F. M. et al. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 19, 1634-1642 (2005). (Pubitemid 43090409)
31. Akiyama, M. et al. Effects of oligonucleotide N3′→P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 63, 6187-6194 (2003). (Pubitemid 37255162)
32. Shammas, M. A. et al. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin. Cancer Res. 10, 770-776 (2004). (Pubitemid 38174015)
33. Brennan, S. K. et al. Telomerase inhib ition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS ONE 5, e12487 (2010).
34. McKenna, R. W. et al. Plasma cell neoplasms. In World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues (eds Swerdlow, S. H. et al.) 200-213 (IARC Press, 2008).
35. Anderson, K. C. New insights into therapeutic targets in myeloma. ASH Education Book 2011, 184-190 (2011).
36. Walker, B. A. et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117, 553-562 (2011).
37. Rasmussen, T. et al. Identification of translocation products but not K-RAS mutations in memory B cells from multiple myeloma patients. Haematologica 95, 1730-1737 (2010).
38. Altieri, A., Chen, B., Bermejo, J. L., Castro, F. & Hemminki, K. Familial risks and temporal incidence trends of multiple myeloma. Eur. J. Cancer 42, 1661-1670 (2006). (Pubitemid 44118762)
39. Broderick, P. et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nature Genet. 44, 58-61 (2012).
40. Bergsagel, P. L. et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106, 296-303 (2005). (Pubitemid 40967205)
41. Chesi, M. et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88, 674-681 (1996). (Pubitemid 26240399)
42. Shaughnessy, J. Jr et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98, 217-223 (2001).
43. Hurt, E. M. et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5, 191-199 (2004). (Pubitemid 38283804)
44. Shou, Y. et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl Acad. Sci. USA 97, 228-233 (2000). (Pubitemid 30055813)
45. Avet-Loiseau, H. et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 98, 3082-3086 (2001).
46. Chesi, M. et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13, 167-180 (2008). (Pubitemid 351163163)
47. Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115-130 (2007). (Pubitemid 47199123)
48. Carrasco, R. et al. Comprehensive genome-wide profile of regional gains and losses in multiple myeloma using array-CGH: The 1q21 amplification and potential role of the BCL-9 gene in multiple myeloma pathogenesis. Blood (ASH Annual Meeting Abstracts) 104, 785 (2004).
49. Keats, J. J. et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 12, 131-144 (2007). (Pubitemid 47208626)
50. Dickens, N. J. et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin. Cancer Res. 16, 1856-1864 (2010).
51. Boyd, K. D. et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin. Cancer Res. 17, 7776-7784 (2011).
52. Jenner, M. W. et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110, 3291-3300 (2007). (Pubitemid 350106322)
53. Leone, P. E. et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin. Cancer Res. 14, 6033-6041 (2008).
54. Gonzalez-Paz, N. et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 109, 1228-1232 (2007). (Pubitemid 46220672)
55. Dib, A., Barlogie, B., Shaughnessy, J. D. Jr & Kuehl, W. M. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 109, 1337-1338 (2007). (Pubitemid 46220692)
56. Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor-κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194, 1861-1874 (2001). (Pubitemid 34028664)
57. Onodera, N., McCabe, N. R. & Rubin, C. M. Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia. Blood 80, 203-208 (1992).
58. Shaughnessy, J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 10 (Suppl. 1), 117-126 (2005). (Pubitemid 41829514)
59. Ley, T. J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72 (2008).
60. Lee, W. et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465, 473-477 (2010).
61. Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011).
62. Aronson, L. I. et al. Autophagy is a key myeloma survival pathway that can be manipulated therapeutically to enhance apoptosis. ASH Annual Meeting Abstracts 116, 4083 (2010).
63. Boyd, K. D. et al. High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk. Lymphoma 51, 2126-2129 (2010).
64. Fazzari, M. J. & Greally, J. M. Epigenomics: beyond CpG islands. Nature Rev. Genet. 5, 446-455 (2004). (Pubitemid 38915411)
65. Chi, P., Allis, C. D. & Wang, G. G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nature Rev. Cancer 10, 457-469 (2010).
66. Cedar, H. & Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nature Rev. Genet. 10, 295-304 (2009).
67. Nimura, K. et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 460, 287-291 (2009).
68. Kim, J. Y. et al. Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol. Cell Biol. 28, 2023-2034 (2008).
69. Marango, J. et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 111, 3145-3154 (2008).
70. Kuo, A. J. et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 44, 609-620 (2011).
71. Martinez-Garcia, E. et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117, 211-220 (2011).
72. Brito, J. L. et al. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica 94, 78-86 (2009).
73. Pei, H. et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 470, 124-128 (2011).
74. Van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genet. 41, 521-523 (2009).
75. Avet-Loiseau, H. et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 28, 4630-4634 (2010).
76. Lode, L. et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 95, 1973-1976 (2010).
77. Boyd, K. D. et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer 50, 765-774 (2011).
78. Pichiorri, F. et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl Acad. Sci. USA 105, 12885-12890 (2008).
79. Pichiorri, F. et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18, 367-381 (2010).
80. Zenz, T. et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114, 2589-2597 (2009).
81. Benetatos, L. & Vartholomatos, G. Deregulated microRNAs in multiple myeloma. Cancer 118, 878-887 (2012).
82. Chang, T. C. et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genet. 40, 43-50 (2008).
83. Boyd, K. D. et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26, 349-355 (2012).
84. Ross, F. M. et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica 95, 1221-1225 (2010).
85. Chauhan, D. et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 87, 1104-1112 (1996). (Pubitemid 26043538)
86. Moreaux, J. et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148-3157 (2004). (Pubitemid 38451693)
87. Neri, P. et al. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood 117, 6202-6213 (2011).
88. Annunziata, C. M. et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 117, 2396-2404 (2011).
89. Wu, P. et al. A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clin. Cancer Res. 17, 6347-6355 (2011).
90. Bezieau, S. et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum. Mutat. 18, 212-224 (2001). (Pubitemid 32807900)
91. Braga, V. M., Betson, M., Li, X. & Lamarche-Vane, N. Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes. Mol. Biol. Cell 11, 3703-3721 (2000).
92. Allan, V. J. Cytoplasmic dynein. Biochem. Soc. Trans. 39, 1169-1178 (2011).
93. Morgan, G. J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376, 1989-1999 (2010).
94. Tian, E. et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483-2494 (2003). (Pubitemid 38010074)
95. Vallet, S. et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc. Natl Acad. Sci. USA 107, 5124-5129 (2010).
96. Avet-Loiseau, H. et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109, 3489-3495 (2007). (Pubitemid 46572539)
97. Avet-Loiseau, H. et al. Prognostic significance of copy-number alterations in multiple myeloma. J. Clin. Oncol. 27, 4585-4590 (2009).
98. Morgan, G. J. et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 118, 1231-1238 (2011).
99. Paiva, B. et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 119, 687-691 (2012).
100. Munshi, N. C. et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117, 4696-4700 (2011).
101. Broyl, A. et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116, 2543-2553 (2010).
102. Zhan, F. et al. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101, 1128-1140 (2003). (Pubitemid 36139388)
103. Nair, B. et al. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood 113, 6572-6575 (2009).
104. Chng, W. J., Glebov, O., Bergsagel, P. L. & Kuehl, W. M. Genetic events in the pathogenesis of multiple myeloma. Best Pract. Res. Clin. Haematol. 20, 571-596 (2007). (Pubitemid 350215376)
105. Kassambara, A. et al. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica 18 Nov 2011 (doi:10.3324/haematol. 2011.046821).
106. Zhan, F. et al. The molecular classification of multiple myeloma. Blood 108, 2020-2028 (2006). (Pubitemid 44395016)
107. Shaughnessy, J. D. Jr et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109, 2276-2284 (2007). (Pubitemid 46425864)
108. Morgan, G. J. et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119, 7-15 (2012).
109. Neben, K. et al. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119, 940-948 (2012).
110. Stewart, A. K. Whole genome sequencing in high-risk myeloma. 13th Annual International Myeloma Workshop 2011 [online] http://www. myeloma-paris2011.com/ content/view/15/10 (2011).
111. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012).
112. Rettig, M. B. et al. VH gene usage in multiple myeloma: complete absence of the VH4.21 (VH4-34) gene. Blood 87, 2846-2852 (1996).
113. Nobuyoshi, M. et al. Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells. Br. J. Haematol. 77, 523-528 (1991).
114. Perez-Rosado, A. et al. BCL6 represses NFκB activity in diffuse large B-cell lymphomas. J. Pathol. 214, 498-507 (2008). (Pubitemid 351340570)